Hostname: page-component-6bf8c574d5-2jptb Total loading time: 0 Render date: 2025-02-14T23:39:10.267Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants

Published online by Cambridge University Press:  01 January 1998

K. YOSHIDA ,
B. SMITH ,
M. CRAGGS  and
R. KUMAR
K. YOSHIDA
Affiliation:
From the Section of Perinatal Psychiatry, Institute of Psychiatry, University of London; and Pathology Laboratory, The Bethlem Royal and Maudsley Hospitals, London
B. SMITH
Affiliation:
From the Section of Perinatal Psychiatry, Institute of Psychiatry, University of London; and Pathology Laboratory, The Bethlem Royal and Maudsley Hospitals, London
M. CRAGGS
Affiliation:
From the Section of Perinatal Psychiatry, Institute of Psychiatry, University of London; and Pathology Laboratory, The Bethlem Royal and Maudsley Hospitals, London
R. KUMAR
Affiliation:
From the Section of Perinatal Psychiatry, Institute of Psychiatry, University of London; and Pathology Laboratory, The Bethlem Royal and Maudsley Hospitals, London
Get access Rights & Permissions [Opens in a new window]

Abstract

Background. Very little is known about the pharmacokinetics of neuroleptic drugs in breast-feeding mothers and their infants or about possible adverse effects in the infants.

Method. Twelve mothers who breast-fed their infants were prescribed haloperidol, chlorpromazine or trifluoperazine. Two methods, enzyme immunoassay (EIA) and high performance liquid chromatography (HPLC) were used to assay these drugs in samples from mothers, but infants' samples were assayed only by the more sensitive EIA. Repeated clinical and developmental assessments of the breast-fed infants were carried out up to 30 months of age. The control subjects were 18 bottle-fed infants whose mothers were also prescribed neuroleptic or mood-stabilizing drugs.

Results. The total concentrations of neuroleptic drugs and their principal metabolites in maternal plasma were correlated with concentrations in fore-milk. Infants were ingesting up to 3% of the maternal daily dose per kg body weight and small amounts of the drugs were detected in infants' plasma and urine. Concentrations of haloperidol in the adult range were found in plasma from 2 of 5 infants assayed by EIA but there was no evidence of any acute or delayed adverse effects. Three other breast-fed infants whose mothers were prescribed both haloperidol and chlorpromazine showed a decline in their developmental scores from the first to the second assessment at 12–18 months.

Conclusion. More extensive longitudinal studies are needed but, in the meantime, there appears to be grounds for caution if breast-feeding mothers are prescribed doses of single or two neuroleptic drugs at the upper end of their recommended ranges.

Type
Research Article
Information
Psychological Medicine , Volume 28 , Issue 1 , January 1998 , pp. 81 - 91
Copyright
© 1998 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)